Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

ExonHit expands collaboration with Allergan
January 2009
SHARING OPTIONS:

PARISóExonHit Therapeutics announced early this month a reinforcement of its existing drug discovery collaboration with Allergan Sales LLC. The collaboration, now extended until December 2011, includes antibody discovery within the scope of the research activities and encompasses revised commercial terms. Detailed financial terms were not disclosed.

The collaboration has been renewed several times since its initiation in December 2002 and focuses on the identification, development and commercialization of drugs for the treatment of neurodegenerative diseases, pain and ophthalmology. EHT/AGN 0001, the most advanced compound out of the collaboration, is currently ending Phase I clinical trials for pain indications. EHT/AGN 0002 and other compounds are in preclinical testing for indications in pain, ophthalmology or neurodegenerative diseases.

The scope of the collaboration was expanded to include epitope discovery for the development of antibody therapeutics in ocular disorders. ExonHit's gene profiling technology can readily be applied to identify disease specific target proteins, but also pinpoints novel epitopes present in those proteins, which are produced via alternative splicing. ExonHit's approach offers the potential benefit of identifying epitopes that are particularly disease-specific, thus enabling the discovery of safer drugs with fewer side effects. In addition, such epitopes may provide the opportunity to create new intellectual property, even in more heavily investigated areas. DDN

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.